-$1.44 Earnings Per Share Expected for Prothena Corporation PLC (PRTA) This Quarter
Equities research analysts predict that Prothena Corporation PLC (NASDAQ:PRTA) will announce ($1.44) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Prothena’s earnings. The lowest EPS estimate is ($1.55) and the highest is ($1.36). Prothena reported earnings per share of ($1.41) during the same quarter last year, which indicates a negative year over year growth rate of 2.1%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 13th.
On average, analysts expect that Prothena will report full-year earnings of ($4.27) per share for the current financial year, with EPS estimates ranging from ($4.39) to ($4.20). For the next financial year, analysts forecast that the business will post earnings of ($5.13) per share, with EPS estimates ranging from ($6.26) to ($3.95). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Prothena.
Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.41) by $0.04. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.28 million. Prothena had a negative net margin of 562.19% and a negative return on equity of 34.40%. Prothena’s revenue for the quarter was down 33.6% on a year-over-year basis. During the same period last year, the firm earned ($1.26) EPS.
Prothena (PRTA) opened at $38.12 on Thursday. Prothena has a fifty-two week low of $37.37 and a fifty-two week high of $70.00.
In other news, insider Tara Nickerson sold 17,500 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the sale, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total transaction of $224,595.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,424 shares of company stock valued at $1,922,787. Insiders own 3.10% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Bank of Montreal Can raised its position in shares of Prothena by 6.7% during the 2nd quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 117 shares in the last quarter. Quantbot Technologies LP raised its position in shares of Prothena by 672.7% during the 2nd quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,628 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Prothena by 187.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 1,549 shares in the last quarter. Strs Ohio raised its position in shares of Prothena by 69.2% during the 3rd quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 900 shares in the last quarter. Finally, Fieldpoint Private Securities LLC purchased a new stake in shares of Prothena during the 3rd quarter valued at $162,000.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.